BioSpace News Archive

Various 0.3% benzalkonium chloride hand sanitizers labelled as “Anti-Microbe” and/or with Drug Identification Number (DIN) 02248351.

National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the fourth quarter ended December 31, 2020. NHI plans to issue its earnings release after the market closes on Monday, February 22, 2021, and will host a conference call on the following day, Tuesday, February 23, 2021, at 12:00 p.m. Eastern Time to discuss the results.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.39 per share.

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies t

XPhyto Therapeutics Corp at the request of OTC Markets, is providing the following comments regarding recent promotional activity with respect to the Corporation. The Corporation has been listed on the Canadian Securities Exchange from July 2019.

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month

Senseonics Holdings, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions.

The National Comprehensive Cancer Network® (NCCN®) put out new information today to provide guidance for COVID-19 vaccinations in people with cancer.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 3,414,970 shares of its common stock, at a purchase price of $1.20 per share

Curelator today announced new data that challenges the age-old belief that stress is a significant factor in triggering migraine attacks[1].